102 related articles for article (PubMed ID: 25510596)
1. Mammary cancer initiation and progression studied with magnetic resonance imaging.
Fan X; Mustafi D; Markiewicz E; Zamora M; Vosicky J; Leinroth A; Mueller J; Macleod K; Conzen SD; Karczmar GS
Breast Cancer Res; 2014 Dec; 16(6):495. PubMed ID: 25510596
[TBL] [Abstract][Full Text] [Related]
2. MRI accurately identifies early murine mammary cancers and reliably differentiates between in situ and invasive cancer: correlation of MRI with histology.
Mustafi D; Zamora M; Fan X; Markiewicz E; Mueller J; Conzen SD; Karczmar GS
NMR Biomed; 2015 Sep; 28(9):1078-86. PubMed ID: 26152557
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging of the natural history of in situ mammary neoplasia in transgenic mice: a pilot study.
Jansen SA; Conzen SD; Fan X; Markiewicz EJ; Newstead GM; Karczmar GS
Breast Cancer Res; 2009; 11(5):R65. PubMed ID: 19732414
[TBL] [Abstract][Full Text] [Related]
4. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
5. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
Green JE; Shibata MA; Yoshidome K; Liu ML; Jorcyk C; Anver MR; Wigginton J; Wiltrout R; Shibata E; Kaczmarczyk S; Wang W; Liu ZY; Calvo A; Couldrey C
Oncogene; 2000 Feb; 19(8):1020-7. PubMed ID: 10713685
[TBL] [Abstract][Full Text] [Related]
6. In vivo MRI of early stage mammary cancers and the normal mouse mammary gland.
Jansen SA; Conzen SD; Fan X; Markiewicz E; Krausz T; Newstead GM; Karczmar GS
NMR Biomed; 2011 Aug; 24(7):880-7. PubMed ID: 21264977
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of mammary lesions represent molecular differences.
Namba R; Maglione JE; Davis RR; Baron CA; Liu S; Carmack CE; Young LJ; Borowsky AD; Cardiff RD; Gregg JP
BMC Cancer; 2006 Dec; 6():275. PubMed ID: 17147824
[TBL] [Abstract][Full Text] [Related]
10. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
11. Detection of in situ mammary cancer in a transgenic mouse model: in vitro and in vivo MRI studies demonstrate histopathologic correlation.
Jansen SA; Conzen SD; Fan X; Krausz T; Zamora M; Foxley S; River J; Newstead GM; Karczmar GS
Phys Med Biol; 2008 Oct; 53(19):5481-93. PubMed ID: 18780960
[TBL] [Abstract][Full Text] [Related]
12. Correlation of In Vivo and Ex Vivo ADC and T2 of In Situ and Invasive Murine Mammary Cancers.
Fan X; Macleod K; Mustafi D; Conzen SD; Markiewicz E; Zamora M; Vosicky J; Mueller J; Karczmar GS
PLoS One; 2015; 10(7):e0129212. PubMed ID: 26208092
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of breast MRI in the management of ductal carcinoma in situ diagnosed on needle biopsy.
Miyashita M; Amano G; Ishida T; Tamaki K; Uchimura F; Ono T; Yajima M; Kuriya Y; Ohuchi N
Jpn J Clin Oncol; 2013 Jun; 43(6):654-63. PubMed ID: 23592884
[TBL] [Abstract][Full Text] [Related]
14. Histological assessment of breast lesions identified exclusively by magnetic resonance.
O'Connor V; Arena E; Albright J; Brown N; O'Connor R; Chung M; DiNome M; Shamonki J
Am Surg; 2014 Oct; 80(10):944-7. PubMed ID: 25264635
[TBL] [Abstract][Full Text] [Related]
15. MRI findings of cancers preoperatively diagnosed as pure DCIS at core needle biopsy.
Huang YT; Cheung YC; Lo YF; Ueng SH; Kuo WL; Chen SC
Acta Radiol; 2011 Dec; 52(10):1064-8. PubMed ID: 21969708
[TBL] [Abstract][Full Text] [Related]
16. T(2)∗ relaxation times of intraductal murine mammary cancer, invasive mammary cancer, and normal mammary gland.
Hipp E; Fan X; Jansen SA; Markiewicz EJ; Vosicky J; Newstead GM; Conzen SD; Krausz T; Karczmar GS
Med Phys; 2012 Mar; 39(3):1309-13. PubMed ID: 22380363
[TBL] [Abstract][Full Text] [Related]
17. MRI ductography of contrast agent distribution and leakage in normal mouse mammary ducts and ducts with in situ cancer.
Markiewicz E; Fan X; Mustafi D; Zamora M; Conzen SD; Karczmar GS
Magn Reson Imaging; 2017 Jul; 40():48-52. PubMed ID: 28366759
[TBL] [Abstract][Full Text] [Related]
18. Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.
Nadrljanski M; Maksimović R; Plešinac-Karapandžić V; Nikitović M; Marković-Vasiljković B; Milošević Z
Eur J Radiol; 2014 Aug; 83(8):1363-7. PubMed ID: 24894697
[TBL] [Abstract][Full Text] [Related]
19. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
20. Ductal carcinoma in situ: is there a role for MRI?
Zuiani C; Francescutti GE; Londero V; Zunnui I; Bazzocchi M
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):89-95. PubMed ID: 12585661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]